Showing results (271-280 of 395) with videos related to
Sort By:
Pageof 40
Genome Medicine|March 20, 2020
Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLLJustyna A Wierzbinska, Reka Toth, Naveed Ishaque, et al.The Lancet. Haematology|August 27, 2021
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna-Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer, et al.The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.Nature Communications|October 20, 2022
Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escapeMaurizio Mangolini, Alba Maiques-Diaz, Stella Charalampopoulou, et al.Blood|May 7, 2014
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaNatali Pflug, Jasmin Bahlo, Tait D Shanafelt, et al.Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.Genes, Chromosomes & Cancer|February 26, 2022
T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic levelPaurnima Patil, Sina Hillebrecht, Emil Chteinberg, et al.European Journal of Haematology|December 9, 2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemiaChristian Maurer, Natali Pflug, Jasmin Bahlo, et al.Leukemia|June 2, 2025
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLLAlena Sophie Ehrmann, Miguel Quijada-Álamo, Viola Close, et al.Pageof 40